ScholarIQanswers from OpenAlex
Multiple Myeloma Research and Treatments
TopicLeading institutions, researchers & key papers
Multiple Myeloma Research and Treatments is a topic indexed in ScholarIQ from OpenAlex.
What is known about Multiple Myeloma Research and Treatments?
ScholarIQrecord summary
This cluster of papers focuses on the diagnosis, staging, treatment, and molecular classification of multiple myeloma. It covers topics such as the International Myeloma Working Group criteria, novel therapies including proteasome inhibitors and immunomodulatory drugs, autologous transplantation, genomic abnormalities, and the role of the bone marrow microenvironment in disease progression.
How many works does Multiple Myeloma Research and Treatments have?
ScholarIQindexed works
Multiple Myeloma Research and Treatments has 198 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Multiple Myeloma Research and Treatments?
ScholarIQopenalex
The OpenAlex for Multiple Myeloma Research and Treatments is on the source record.
What are the most-cited papers on Multiple Myeloma Research and Treatments?
ScholarIQmost cited works
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar, Bruno Paiva, Kenneth C. Anderson, Brian G.M. Durie, Ola Landgren, Philippe Moreau, Nikhil C. Munshi, Sagar Lonial, Joan Bladé, María‐Victoria Mateos, Meletios Α. Dimopoulos, Efstathios Kastritis, Mario Boccadoro, Robert Z. Orlowski, Hartmut Goldschmidt, Andrew Spencer, Jian Hou, Wee Joo Chng, Saad Z. Usmani, Elena Zamagni, Kazuyuki Shimizu, Sundar Jagannath, Hans Erik Johnsen, Evangelos Terpos, Tony Reiman, Robert A. Kyle, Pieter Sonneveld, Paul G. Richardson, Philip L. McCarthy, Heinz Ludwig, Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Seema Singhal, Jayesh Mehta, Raman Desikan, Dan Ayers, Paula K. Roberson, Paul Eddlemon, Nikhil C. Munshi, Elias Anaissie, Carla S. Wilson, Madhav V. Dhodapkar, Jerome B. Zeldis, David S. Siegel, John Crowley, Bart Barlogie
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Krönke, Namrata D. Udeshi, Anupama Narla, Peter Grauman, Slater N. Hurst, Marie McConkey, Tanya Svinkina, Dirk Heckl, Eamon Comer, Xiaoyu Li, Christie Ciarlo, Emily C. Hartman, Nikhil C. Munshi, Monica Schenone, Stuart L. Schreiber, Steven A. Carr, Benjamin L. Ebert
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin, Xavier Leleu, Denis Caillot, Martine Escoffre, Bertrand Arnulf, Margaret Macro, Karim Belhadj, Laurent Garderet, Murielle Roussel, Catherine Payen, Claire Mathiot, Jean Paul Fermand, Nathalie Meuleman, Sandrine Rollet, Michelle E. Maglio, Andrea A. Zeytoonjian, Edie Weller, Nikhil C. Munshi, Kenneth C. Anderson, Paul G. Richardson, Thierry Façon, Hervé Avet‐Loiseau, Jean‐Luc Harousseau, Philippe Moreau
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel, Albert Oriol, Ajay K. Nooka, Thomas G. Martin, Laura Rosiñol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun Xin Wang Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani
Where is Multiple Myeloma Research and Treatments research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Multiple Myeloma Research and Treatments is open access?
ScholarIQopen access share
80%OPEN ACCESS